The Quantellect read.As of Nov 19, 2026, 4 active firms cover Benitec Biopharma Inc: 4 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $14.00 to $32.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $22.00 sits 166% above the current $8.26. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.31 next quarter toward $-1.44 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy4100%
Neutral00%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$22.00
+166.3% upside
Average target across 4 active firms as of Nov 19, 2026 vs $8.26 current
Highest Target$32.00
Average Target$22.00
Lowest Target$14.00
Detailed analyst forecasts for BNTC
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 4 of 4 active firms rate BNTC a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BNTC EPS & revenue forecast
EPS · NEXT QUARTER
$-0.31
Range $-0.37 – $-0.25 · 6 analysts · +29% YoY
Next period, 6 analysts expect Benitec Biopharma Inc. to earn $-0.31 a share (range $-0.37 – $-0.25), versus $-0.24 a year earlier. Full-year consensus is $-1.19, growing to $-1.44 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 6 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Benitec Biopharma Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BNTC.
#1
Silvan Tuerkcan
JMP Securities · Rank #69
Buy
$22.00+166.3% to target
Overall win rate
51%
+ Follow
#2
Debjit Chattopadhyay
Guggenheim · Rank #248
Neutral
No targeton BNTC
Overall win rate
39%
+ Follow
#3
Yasmeen Rahimi
Piper Sandler · Rank #339
Buy
$30.00+263.2% to target
Overall win rate
30%
+ Follow
#4
Andreas Argyrides
Oppenheimer · Rank #380
Buy
$29.00+251.1% to target
Overall win rate
41%
+ Follow
#5
Raghuram Selvaraju
HC Wainwright & Co. · Rank #423
Buy
$32.00+287.4% to target
Overall win rate
36%
+ Follow
BNTC stock forecast FAQ
What is BNTC's average 12-month price target?+
The 4 active firms with a live target average $22.00 for Benitec Biopharma Inc. over the next 12 months, ranging from a $32.00 high to a $14.00 low, as of Nov 19, 2026.
Is BNTC stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BNTC?+
The Street-high target is $32.00 (HC Wainwright & Co.), and the Street-low is $14.00 (Raymond James). The average of all 4 active-firm targets is $22.00.
How many active Wall Street firms cover BNTC?+
4 active firms have a recognized rating on Benitec Biopharma Inc. as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BNTC?+
Among analysts who currently cover BNTC, Silvan Tuerkcan of JMP Securities has the strongest overall Quantellect track record (Rank #69). Their current call is Buy with a $22.00 target.
What is Benitec Biopharma Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.31 per share (range $-0.37 – $-0.25) across 6 analysts. Full-year EPS is projected at $-1.19, rising to $-1.44 the following year.
How much revenue is Benitec Biopharma Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading BNTC lately?+
As of Nov 19, 2026, 4 of 4 active firms rate BNTC a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BNTC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.